Incidence of venous thromboembolism remains 'substantial' despite expert guidelines and newer risk prediction scores ...

Iberdomide and mezigdomide are currently being evaluated for the treatment of patients with multiple myeloma in a number of ...

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have uncovered biological differences ...

Patients share their unexpected journeys with multiple myeloma, revealing challenges and resilience in the face of a cancer ...

At ASH 2025, iMMagine-1 data showed that anito-cel has a favorable and durable safety profile with low rates of severe CRS, neurotoxicity, and infections.

Patients share their emotional journeys and coping strategies after cancer diagnoses, highlighting the importance of support ...

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

The FDA has “proactively” granted Johnson & Johnson a coveted speedy review under the Commissioner’s National Priority ...

The latest data released at ASH 2025 offer new combination therapies for the treatment of multiple myeloma and new insights into the disease.

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted ...

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% ...

As a hematologist with a keen interest in multiple myeloma who’s looking forward to the 2025 American Society of Hematology (ASH) Annual Meeting and Exposition in December, I’ve picked out this list ...